Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits

被引:27
作者
Etienne, M
Croisier, D
Charles, PE
Lequeu, C
Piroth, L
Portier, H
Drlica, K
Chavanet, P
机构
[1] Hop Bocage, Serv Malad Infect, F-21079 Dijon, France
[2] Publ Hlth Res Inst, Newark, NJ USA
关键词
D O I
10.1086/423853
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We measured the effect of low-level fluoroquinolone resistance in Streptococcus pneumoniae on the development of high-level resistance within the context of the mutant selection window. Methods. Rabbits infected with S. pneumoniae were treated with ciprofloxacin or moxifloxacin concentrations that simulated pharmacokinetics in treated humans; bacteria obtained from lungs were examined for fluoroquinolone susceptibility. Results. Ciprofloxacin enriched resistant mutants from a wild-type strain; moxifloxacin did not. However, moxifloxacin enriched resistant mutants from a parC mutant; the drug concentration at the top of the selection window was determined. Conclusions. A parC resistance mutation facilitates the enrichment of high-level resistance, as was predicted by in vitro measurements.
引用
收藏
页码:1472 / 1475
页数:4
相关论文
共 14 条
[1]  
Baquero F, 1997, J CHEMOTHERAPY, V9, P29
[2]   Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones [J].
Croisier, D ;
Chavanet, P ;
Lequeu, C ;
Ahanou, A ;
Nierlich, A ;
Neuwirth, C ;
Piroth, L ;
Duong, M ;
Buisson, M ;
Portier, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (03) :349-360
[3]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750
[4]   Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000 [J].
Davies, TA ;
Evangelista, A ;
Pfleger, S ;
Bush, K ;
Sahm, DF ;
Goldschmidt, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :119-124
[5]   Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States [J].
Doern, GV .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S187-S192
[6]  
Drlica K, 2003, REV MED MICROBIOL, V14, P95
[7]   Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae [J].
Fukuda, H ;
Kishii, R ;
Takei, M ;
Hosaka, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1649-1653
[8]   Increasing resistance of Streptococcus pneumoniae to fluoroquinolones:: results of a Hong Kong multicentre study in 2000 [J].
Ho, PL ;
Yung, RWH ;
Tsang, DNC ;
Que, TL ;
Ho, M ;
Seto, WH ;
Ng, TK ;
Yam, WC ;
Ng, WWS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) :659-665
[9]   PHARMACOKINETIC PROFILES OF CIPROFLOXACIN AFTER SINGLE INTRAVENOUS AND ORAL DOSES [J].
LETTIERI, JT ;
ROGGE, MC ;
KAISER, L ;
ECHOLS, RM ;
HELLER, AH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :993-996
[10]   Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin [J].
Li, XY ;
Zhao, XL ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :522-524